Trial Profile
Effect of genomic signature in predicting baseline resistance to Nivolumab in advanced Non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PRINCiPe
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer